Method for detecting CAPRIN-1 in a biological sample

This invention provides: a method for detecting a cancer, comprising measuring the expression of a polypeptide having binding reactivity through antigen-antibody reaction with an antibody against CAPRIN-1 having an amino acid sequence shown in any even-numbered SEQ ID NO shown in SEQ ID NOs: 2 to 30 in the Sequence Listing in a biological sample; a method for detecting a cancer which involves determining the presence and the amount of CAPRIN-1 in a sample of a cancer patient in order to determine the administration of a therapeutic drug targeting CAPRIN-1 to the cancer patient; and a drug and a kit for the diagnosis of a cancer, comprising an anti-CAPRIN-1 antibody.

Pharmaceutical composition for treatment and prevention of cancers

The present invention relates to a pharmaceutical composition for treatment and/or prevention of cancer, which comprises, as an active ingredient, an antibody or fragment thereof having an immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising 7 or more consecutive amino acids.

Pharmaceutical composition for treatment and/or prevention of gallbladder cancer

Provided is an antibody effective for treatment and/or prevention of gallbladder cancer. A pharmaceutical composition for treatment and/or prevention of gallbladder cancer contains as an active ingredient an antibody or a fragment thereof having immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising at least seven consecutive amino acid residues of the amino acid sequence of the protein.

Immune response inducer

An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or prophylactic agent for a cancer(s).

Method for detecting cancer via measurement of caprin-1 expression level

This invention provides: a method for detecting a cancer, comprising measuring the expression of a polypeptide having binding reactivity through antigen-antibody reaction with an antibody against CAPRIN-1 having the amino acid sequence shown in any even-numbered SEQ ID NO of SEQ ID NOs: 2 to 30 in the Sequence Listing in a biological sample; a method for detecting a cancer which involves determining the presence and the amount of CAPRIN-1 in a sample of a cancer patient in order to determine the administration of a CAPRIN-1-targeting drug to the cancer patient; and a drug and a kit for the diagnosis of a cancer, comprising an anti-CAPRIN-1 antibody.

Pharmaceutical composition for treatment and/or prevention of pancreatic cancer

This invention relates to a pharmaceutical composition for treatment and/or prevention of pancreatic cancer, comprising as an active ingredient an antibody or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising 7 to 12 or more consecutive amino acid residues.

Method for inducing immunity with a peptide fragment from human CAPRIN-1

The invention relates to an immunity-inducing agent comprising, as an active ingredient, at least one polypeptide having immunity-inducing activity that is selected from among polypeptides (a), (b), and (c): (a) a polypeptide of at least seven contiguous amino acids of the amino acid sequence shown by any even SEQ ID number selected from SEQ ID NOs: 2 to 30 listed in the Sequence Listing; (b) a polypeptide of at least seven amino acids having 90% or more sequence identity with the polypeptide (a); and (c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof, or a recombinant vector comprising a polynucleotide encoding said polypeptide and capable of expressing said polypeptide in vivo.

Pharmaceutical composition for treatment and/or prevention of liver cancer

Provided is an antibody effective for treatment and/or prevention of liver cancer. A pharmaceutical composition for treatment and/or prevention of liver cancer contains as an active ingredient an antibody or a fragment thereof having immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising at least seven consecutive amino acid residues of the amino acid sequence of the protein.

Immunity induction agent

Provided is a novel immunity induction agent useful as a cancer treatment and/or prevention agent or the like. The immunity induction agent contains, as an active ingredient: at least one polypeptide having immunity induction activity and selected from polypeptides (a), (b), and (c), namely, (a) a polypeptide comprising at least seven successive amino acids in the amino acid sequence indicated by sequence numbers 4, 2, 22, or 24 in the sequence table, (b) a polypeptide comprising at least seven amino acids and having a sequence identity of at least 90% with respect to polypeptide (a), and (c) a polypeptide containing polypeptide (a) or (b) as a partial sequence.

Pharmaceutical composition for treatment and/or prevention of cancer

It is intended to provide a CAPRIN-1-targeting antibody superior in antitumor activity to conventional antibodies, and use thereof as a therapeutic and/or preventive agent for a cancer. The present invention provides an antibody targeting a CAPRIN-1 polypeptide specifically expressed on the surface of cancer cells, and use of the antibody as a therapeutic and/or preventive agent for a cancer. The present invention provides an antibody which comprises a heavy chain variable region comprising complementarity-determining regions of SEQ ID NOs: 1, 2, and 3 and a light chain variable region comprising complementarity-determining regions of SEQ ID NOs: 4, 5, and 6 and has immunological reactivity with a CAPRIN-1 protein, or a fragment thereof, and a pharmaceutical composition for the treatment and/or prevention of a cancer, comprising this antibody or fragment as an active ingredient.

Pharmaceutical composition for treatment and/or prevention of cancer

According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen protein as an agent for treating and/or preventing a cancer is provided. Specifically, the present invention provides a pharmaceutical composition for treating and/or preventing a cancer, which comprises an antibody or a fragment thereof as an active ingredient having immunological reactivity with a partial polypeptide of CAPRIN-1, wherein CAPRIN-1 is represented by any of the even-numbered sequences of SEQ ID NOS: 2 to 30, and wherein the partial polypeptide comprises the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence.

Pharmaceutical composition for treatment of cancer comprising an anti-CAPRIN-1 peptide antibody

The invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof in a therapeutic and/or preventive agent for cancer. Specifically, this invention provides an antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence, and a pharmaceutical composition for treatment and/or prevention of cancer, comprising the antibody or fragment thereof as an active ingredient.

Method for detecting pancreatic cancer

This invention relates to a method for detecting pancreatic cancer using novel tumor markers. Specifically, the invention provides a method for detecting pancreatic cancer comprising measuring the presence or an amount of a polypeptide having an reactivity of binding via an antigen-antibody reaction to an antibody against CAPRIN-1 protein in a sample separated from a subject, and to a reagent or kit for detecting pancreatic cancer comprising a CAPRIN-1 protein or a fragment thereof, an antibody against the same, or a polynucleotide encoding the same.

Immunity inducing agent

Provided is a novel immunity inducing agent that is useful as a cancer treatment and/or prevention agent or the like. The immunity inducing agent contains, as an active ingredient: at least one polypeptide having immunity inducing activity and selected from polypeptides (a), (b), and (c), namely, (a) a polypeptide comprising at least seven successive amino acids in the amino acid sequence indicated by sequence number 4, 2, 8, 10, or 12 in the sequence table, (b) a polypeptide comprising at least seven amino acids and having a sequence identity of at least 85% with respect to polypeptide (a), and (c) a polypeptide containing polypeptide (a) or (b) as a partial sequence; or a recombinant vector that can express the polypeptide in vivo and contains a polynucleotide that codes for the polypeptide.

MEDICAMENT FOR TREATING AND/OR PREVENTING CANCER

This invention relates to a medicament for treating and/or preventing a cancer, comprising a combination of an antibody against a cancer antigen CAPRIN-1 protein that is specifically expressed on the surface of the cancer cell, and an antitumor agent, wherein the antibody and the antitumor agent are combined together or separately, and to a use of the medicament. 1. A medicament for treating and/or preventing a cancer , comprising a combination of an antibody or a fragment thereof having immunological reactivity with a CAPRIN-1 protein , and one or two or more types of antitumor agent , wherein the antibody or fragment and the antitumor agent or antitumor agents are combined together or separately.2. The medicament according to claim 1 , wherein the antibody or a fragment thereof having immunological reactivity with a CAPRIN-1 protein is an antibody or a fragment thereof claim 1 , which binds specifically to the extracellular region of a CAPRIN-1 protein existing on the surface of a cancer cell.3. The medicament according to claim 1 , wherein the antibody or a fragment thereof having immunological reactivity with a CAPRIN-1 protein is an antibody or a fragment thereof claim 1 , which binds specifically to a polypeptide having the amino acid sequence represented by SEQ ID NO: 37 in the extracellular region of the CAPRIN-1 protein existing on the surface of a cancer cell claim 1 , or an amino acid sequence having 80% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 37.4. The medicament according to claim 1 , wherein the CAPRIN-1 protein is from a human.5. The medicament according to claim 1 , wherein the above antitumor agent is any of the antitumor agents as described in the description.6. The medicament according to claim 5 , wherein the antitumor agent is selected from the group consisting of cyclophosphamide claim 5 , paclitaxel claim 5 , docetaxel claim 5 , vinorelbine claim 5 , and pharmaceutically acceptable salts and derivatives ...

PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER

According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen protein as an agent for treating and/or preventing a cancer is provided. Specifically, the present invention provides a pharmaceutical composition for treating and/or preventing a cancer, which comprises an antibody or a fragment thereof as an active ingredient having immunological reactivity with a partial polypeptide of CAPRIN-1, wherein CAPRIN-1 is represented by any of the even-numbered sequences of SEQ ID NOS: 2 to 30, and wherein the partial polypeptide comprises the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence. 1. A pharmaceutical composition for treating and/or preventing a cancer , comprising an antibody or a fragment thereof as an active ingredient that has immunological reactivity with a partial polypeptide of CAPRIN-1 , wherein CAPRIN-1 is represented by any of the even-numbered sequences of SEQ ID NOS: 2 to 30 , and wherein the partial polypeptide comprises the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence of SEQ ID NO: 37.2. The pharmaceutical composition according to claim 1 , wherein the cancer is breast cancer claim 1 , brain tumor claim 1 , leukemia claim 1 , lymphoma claim 1 , lung cancer claim 1 , mastocytoma claim 1 , renal cancer claim 1 , uterine cervix cancer claim 1 , bladder cancer claim 1 , esophageal cancer claim 1 , gastric cancer claim 1 , or colorectal cancer.3. The pharmaceutical composition according to claim 1 , wherein the antibody is a monoclonal antibody or a polyclonal antibody.4. The pharmaceutical composition according to claim 1 , wherein the antibody is a human antibody claim 1 , humanized antibody claim 1 , chimeric antibody claim 1 , single ...

PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER

According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen protein as an agent for treating and/or preventing a cancer is provided. Specifically, the present invention provides a pharmaceutical composition for treating and/or preventing a cancer, which comprises an antibody or a fragment thereof as an active ingredient having immunological reactivity to a partial polypeptide of CAPRIN-1, which is represented by any of even-numbered sequences of SEQ ID NOS: 2 to 30, wherein the polypeptide has the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence. 1. A pharmaceutical composition for treating and/or preventing a cancer , comprising an antibody or a fragment thereof as an active ingredient that has immunological reactivity with a partial polypeptide of CAPRIN-1 , wherein CAPRIN-1 is represented by any of the even-numbered sequences of SEQ ID NOS: 2 to 30 , and wherein the partial polypeptide comprises the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence of SEQ ID NO: 37.2. A pharmaceutical composition for treating and/or preventing a cancer , comprising an antibody or a fragment thereof as an active ingredient that has immunological reactivity with a partial polypeptide of CAPRIN-1 , wherein CAPRIN-1 is represented by any of the even-numbered sequences of SEQ ID NOS: 2 to 30 , and wherein the partial polypeptide comprises the amino acid sequence represented by SEQ ID NO: 69 or 70 contained in the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence of SEQ ID NO: 69 or 70.3. The pharmaceutical composition according to or , wherein the cancer is breast cancer , brain ...

PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER

According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen protein as an agent for treating and/or preventing a cancer is provided. Specifically, the present invention provides a pharmaceutical composition for treating and/or preventing a cancer, which comprises an antibody or a fragment thereof as an active ingredient having immunological reactivity with a partial polypeptide of CAPRIN-1, wherein CAPRIN-1 is represented by any of the even-numbered sequences of SEQ ID NOS: 2 to 30, and wherein the partial polypeptide comprises the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence. 1. A pharmaceutical composition for treating and/or preventing a cancer , comprising an antibody or a fragment thereof as an active ingredient that has immunological reactivity with a partial polypeptide of CAPRIN-1 , wherein CAPRIN-1 is represented by any of the even-numbered sequences of SEQ ID NOS: 2 to 30 , and wherein the partial polypeptide comprises the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence of SEQ ID NO: 37.2. The pharmaceutical composition according to claim 1 , wherein the cancer is breast cancer claim 1 , brain tumor claim 1 , leukemia claim 1 , lymphoma claim 1 , lung cancer claim 1 , mastocytoma claim 1 , renal cancer claim 1 , uterine cervix cancer claim 1 , bladder cancer claim 1 , esophageal cancer claim 1 , gastric cancer claim 1 , or colorectal cancer.3. The pharmaceutical composition according to claim 1 , wherein the antibody is a monoclonal antibody or a polyclonal antibody.4. The pharmaceutical composition according to claim 1 , wherein the antibody is a human antibody claim 1 , humanized antibody claim 1 , chimeric antibody claim 1 , single ...

PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER

According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen protein as an agent for treating and/or preventing cancer is provided. Specifically, the present invention provides a pharmaceutical composition for treating and/or preventing a cancer, which comprises an antibody or a fragment thereof as an active ingredient having immunological reactivity with a partial polypeptide of CAPRIN-1, which is represented by any of even-numbered sequences of SEQ ID NOS: 2 to 30, wherein the polypeptide has the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 37. 1. A pharmaceutical composition for treating and/or preventing a cancer , comprising an antibody or a fragment thereof as an active ingredient that has immunological reactivity with a partial polypeptide of CAPRIN-1 , wherein CAPRIN-1 is represented by any of the even-numbered sequences of SEQ ID NOS: 2 to 30 , and wherein the partial polypeptide comprises the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence of SEQ ID NO: 37.2. The pharmaceutical composition according to claim 1 , wherein the cancer is breast cancer claim 1 , brain tumor claim 1 , leukemia claim 1 , lymphoma claim 1 , lung cancer claim 1 , mastocytoma claim 1 , renal cancer claim 1 , uterine cervix cancer claim 1 , bladder cancer claim 1 , esophageal cancer claim 1 , gastric cancer claim 1 , or colorectal cancer.3. The pharmaceutical composition according to claim 1 , wherein the antibody is a monoclonal antibody or a polyclonal antibody.4. The pharmaceutical composition according to claim 1 , wherein the antibody is a human antibody claim 1 , humanized antibody claim 1 , chimeric antibody claim 1 , single chain ...

METHOD FOR INDUCING IMMUNITY WITH A PEPTIDE FRAGMENT FROM HUMAN CAPRIN-1

The invention relates to an immunity-inducing agent comprising, as an active ingredient, at least one polypeptide having immunity-inducing activity that is selected from among polypeptides (a), (b), and (c): (a) a polypeptide of at least seven contiguous amino acids of the amino acid sequence shown by any even SEQ ID number selected from SEQ ID NOs: 2 to 30 listed in the Sequence Listing; (b) a polypeptide of at least seven amino acids having 90% or more sequence identity with the polypeptide (a); and (c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof, or a recombinant vector comprising a polynucleotide encoding said polypeptide and capable of expressing said polypeptide in vivo. 1. An immunity-inducing agent comprising , as an active ingredient , at least one polypeptide having immunity-inducing activity and selected from the following polypeptides (a) , (b) , and (c) , or a recombinant vector comprising a polynucleotide encoding said polypeptide and capable of expressing said polypeptide in vivo:(a) a polypeptide of at least seven contiguous amino acids of the amino acid sequence shown by any even SEQ ID number selected from SEQ ID NOs: 2 to 30 listed in the Sequence Listing;(b) a polypeptide of at least seven amino acids having 90% or more sequence identity with the polypeptide (a); and(c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof.2. The immunity-inducing agent according to claim 1 , wherein the polypeptide (b) is a polypeptide having 95% or more sequence identity with the polypeptide (a).3. The immunity-inducing agent according to claim 1 , wherein the polypeptide having immunity-inducing activity is a polypeptide of at least seven contiguous amino acids of the amino acid sequence shown by any even SEQ ID number selected from SEQ ID NOs: 2 to 30 listed in the Sequence Listing claim 1 , or a polypeptide comprising said polypeptide as a partial sequence thereof.4. The immunity-inducing ...

PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER

This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof in a therapeutic and/or preventive agent for cancers. Specifically, this invention provides an antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence, and a pharmaceutical composition for treatment and/or prevention of cancers, comprising the antibody or fragment thereof as an active ingredient. 1. An antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide having the amino acid sequence represented by SEQ ID NO: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence.2. The antibody or fragment thereof according to claim 1 , wherein the antibody or fragment thereof has cytotoxic activity against a cancer cell expressing a CAPRIN-1 protein.3. The antibody or fragment thereof according to claim 1 , wherein the antibody is a monoclonal antibody or a polyclonal antibody.4. The antibody or fragment thereof according to claim 1 , wherein the antibody is a human antibody claim 1 , a humanized antibody claim 1 , a chimeric antibody claim 1 , a single-chain antibody claim 1 , or a multispecific antibody.5. The antibody or fragment thereof according to claim 1 , wherein the antibody or fragment thereof comprises a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 8 claim 1 , 9 claim 1 , and 10 (CDR1 claim 1 , CDR2 claim 1 , and CDR3 claim 1 , respectively) and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 12 claim 1 , 13 claim 1 , and 14 (CDR1 claim 1 , CDR2 claim 1 , and CDR3 claim 1 , respectively) and has immunological reactivity with the CAPRIN-1 protein.6. The ...

PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER

This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof in a therapeutic and/or preventive agent for cancer. Specifically, this invention provides an antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence, and a pharmaceutical composition for treatment and/or prevention of cancer, comprising the antibody or fragment thereof as an active ingredient. 1. An antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence.2. The antibody or fragment thereof according to claim 1 , wherein the antibody or fragment thereof has cytotoxic activity against a cancer cell expressing a CAPRIN-1 protein.3. The antibody or fragment thereof according to claim 1 , wherein the antibody is a monoclonal antibody or a polyclonal antibody.4. The antibody or fragment thereof according to claim 1 , wherein the antibody is a human antibody claim 1 , a humanized antibody claim 1 , a chimeric antibody claim 1 , a single-chain antibody claim 1 , or a multispecific antibody.5. The antibody or fragment thereof according to claim 1 , wherein the antibody or fragment thereof comprises a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 8 claim 1 , 9 claim 1 , and 10 (CDR1 claim 1 , CDR2 claim 1 , and CDR3 claim 1 , respectively) and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 12 claim 1 , 13 claim 1 , and 14 (CDR1 claim 1 , CDR2 claim 1 , and CDR3 claim 1 , respectively) and has immunological reactivity with the CAPRIN-1 protein.6. The ...

IMMUNITY INDUCING AGENT

Provided is a method for inducing immunity for therapy of a cancer(s). The method includes the step of administering to an individual with cancer at least one polypeptide selected from the polypeptides (a) or (b) below, and/or a recombinant vector(s) that comprise(s) a polynucleotide(s) encoding the at least one polypeptide, the recombinant vector(s) being capable of expressing the polypeptide(s) in vivo: (a) a polypeptide in any one of the amino acid sequences of SEQ ID NOs: 2, 4, 8, 10 and 12; and (b) a polypeptide having a sequence identity of not less than 95% to the polypeptide (a). 1. A method for inducing immunity for therapy of a cancer(s) , said method comprising:administering to an individual with cancer at least one polypeptide selected from the polypeptides (a) or (b) below, and/or a recombinant vector(s) that comprise(s) a polynucleotide(s) encoding said at least one polypeptide, said recombinant vector(s) being capable of expressing said polypeptide(s) in vivo:(a) a polypeptide in any one of the amino acid sequences of SEQ ID NOs: 2, 4, 8, 10 and 12; and(b) a polypeptide having a sequence identity of not less than 95% to said polypeptide (a).2. The method according to claim 1 , wherein said cancer(s) is/are a cancer(s) expressing KATANAL1.3. The method according to claim 1 , wherein said cancer(s) is/are breast cancer claim 1 , brain tumor claim 1 , perianal adenocarcinoma claim 1 , neuroblastoma claim 1 , mastocytoma claim 1 , liver cancer claim 1 , prostate cancer claim 1 , lung cancer claim 1 , thyroid cancer claim 1 , and/or leukemia.4. The method according to claim 1 , further administering an immunoenhancer.5. The method according to claim 1 , wherein said immunoenhancer is at least one selected from the group consisting of Freund's incomplete adjuvant Montanide claim 1 , poly-LC and derivatives thereof claim 1 , CpG oligonucleotides claim 1 , interleukin-12 claim 1 , interleukin-18 claim 1 , interferon-α claim 1 , interferon-β claim 1 , ...

IMMUNITY INDUCING AGENT

Provided is a novel immunity-inducing agent useful as a therapeutic and/or prophylactic agent for cancer. The immunity-inducing agent comprises as an effective ingredient(s) at least one polypeptide having immunity-inducing activity selected from the polypeptides (a), (b) and (c) below, and/or a recombinant vector(s) that comprise(s) a polynucleotide(s) encoding the at least one polypeptide, which recombinant vector(s) is/are capable of expressing the polypeptide(s) in vivo: (a) a polypeptide composed of not less than 7 consecutive amino acids in any one of the amino acid sequences of SEQ ID NOs:4, 2, 8, 10 and 12 in SEQUENCE LISTING; (b) a polypeptide having a sequence identity of not less than 85% to the polypeptide (a) and composed of not less than 7 amino acids; and (c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof. 1. An immunity-inducing agent comprising as an effective ingredient(s) at least one polypeptide having immunity-inducing activity selected from the polypeptides (a) to (c) below , and/or a recombinant vector(s) that comprise(s) a polynucleotide(s) encoding said at least one polypeptide , said recombinant vector(s) being capable of expressing said polypeptide(s) in vivo:(a) a polypeptide composed of not less than 7 consecutive amino acids in any one of the amino acid sequences of SEQ ID NOs:4, 2, 8, 10 and 12 in SEQUENCE LISTING;(b) a polypeptide having a sequence identity of not less than 85% to said polypeptide (a) and composed of not less than 7 amino acids; and(c) a polypeptide comprising said polypeptide (a) or (b) as a partial sequence thereof.2. The immunity-inducing agent according to claim 1 , wherein said polypeptide having immunity-inducing activity is a polypeptide having the amino acid sequence of SEQ ID NO:4 claim 1 , 2 claim 1 , 8 claim 1 , 10 or 12 in SEQUENCE LISTING.3. The immunity-inducing agent according to claim 1 , which is an agent for treating antigen-presenting cells.4. The immunity-inducing ...

IMMUNE RESPONSE INDUCER

An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or prophylactic agent for a cancer(s). 1. A method for inducing immunity , said method comprising administering to an individual an effective amount of any one of the polypeptides (a) to (c) below , said polypeptide having an immunity-inducing activity:(a) a polypeptide consisting of not less than 7 consecutive amino acids of the amino acid sequence shown in SEQ ID NO: 2 or 4 in SEQUENCE LISTING;(b) a polypeptide having a homology of not less than 80% to the polypeptide (a) and consisting of not less than 7 amino acids; and(c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof.2. A method for inducing immunity , said method comprising administering to an individual an effective amount of a recombinant vector which comprises a polynucleotide encoding an immunity-inducing polypeptide selected from any one of the polypeptides (a) to (c) below , said recombinant vector being capable of expressing said polypeptide in vivo:(a) a polypeptide consisting of not less than 7 consecutive amino acids of the amino acid sequence shown in SEQ ID NO:2 or 4 in SEQUENCE LISTING;(b) a polypeptide having a homology of not less than 80% to the polypeptide (a) and consisting of not less than 7 amino acids; and(c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof. This application is a Divisional of U.S. patent application Ser. No. 12/739,723 filed on Apr. 23, 2010, which is the ...

IMMUNE RESPONSE INDUCER

An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or prophylactic agent for a cancer(s). 1. A method for inducing immunity , said method comprising administering to an individual an effective amount of any one of the polypeptides (a) to (c) below , said polypeptide having an immunity-inducing activity:(a) a polypeptide consisting of not less than 7 consecutive amino acids of the amino acid sequence shown in SEQ ID NO: 39 or 41 in SEQUENCE LISTING;(b) a polypeptide having a homology of not less than 80% to the polypeptide (a) and consisting of not less than 7 amino acids; and(c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof.2. A method for inducing immunity , said method comprising administering to an individual an effective amount of a recombinant vector which comprises a polynucleotide encoding an immunity-inducing polypeptide selected from any one of the polypeptides (a) to (c) below , said recombinant vector being capable of expressing said polypeptide in vivo:(a) a polypeptide consisting of not less than 7 consecutive amino acids of the amino acid sequence shown in SEQ ID NO: 39 or 41 in SEQUENCE LISTING;(b) a polypeptide having a homology of not less than 80% to the polypeptide (a) and consisting of not less than 7 amino acids; and(c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof. This application is a Divisional of U.S. patent application Ser. No. 12/739,723 filed on Apr. 23, 2010, which is the ...

IMMUNE RESPONSE INDUCER

An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or prophylactic agent for a cancer(s). 1. A method for inducing immunity , said method comprising administering to an individual an effective amount of any one of the polypeptides (a) to (c) below , said polypeptide having an immunity-inducing activity:(a) a polypeptide consisting of not less than 7 consecutive amino acids of the amino acid sequence shown in SEQ ID NO: 26, 28 or 30 in SEQUENCE LISTING;(b) a polypeptide having a homology of not less than 80% to the polypeptide (a) and consisting of not less than 7 amino acids; and(c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof.2. A method for inducing immunity , said method comprising administering to an individual an effective amount of a recombinant vector which comprises a polynucleotide encoding an immunity-inducing polypeptide selected from any one of the polypeptides (a) to (c) below , said recombinant vector being capable of expressing said polypeptide in vivo:(a) a polypeptide consisting of not less than 7 consecutive amino acids of the amino acid sequence shown in SEQ ID NO: 26, 28 or 30 in SEQUENCE LISTING;(b) a polypeptide having a homology of not less than 80% to the polypeptide (a) and consisting of not less than 7 amino acids; and(c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof. This application is a Divisional of U.S. patent application Ser. No. 12/739,723 filed on Apr. 23, 2010, which ...

Pharmaceutical composition for treatment and/or prevention of cancer

This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof as a therapeutic and/or preventive agent for cancer. Specifically, this invention provides an antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence, and a pharmaceutical composition for treatment and/or prevention of cancer, comprising the antibody or fragment thereof as an active ingredient.

PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER

The invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof in a therapeutic and/or preventive agent for cancer. Specifically, this invention provides an antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence, and a pharmaceutical composition for treatment and/or prevention of cancer, comprising the antibody or fragment thereof as an active ingredient. 1. An antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence.2. The antibody or fragment thereof according to claim 1 , wherein the antibody or fragment thereof has cytotoxic activity against a cancer cell expressing a CAPRIN-1 protein.3. The antibody or fragment thereof according to claim 1 , wherein the antibody is a monoclonal antibody or a polyclonal antibody.4. The antibody or fragment thereof according to claim 1 , wherein the antibody is a human antibody claim 1 , a humanized antibody claim 1 , a chimeric antibody claim 1 , a single-chain antibody claim 1 , or a multispecific antibody.5. The antibody or fragment thereof according to claim 1 , wherein the antibody or fragment thereof comprises a heavy chain variable region comprising complementarity determining regions consisting of the amino acid sequence shown in SEQ ID NOs: 8 claim 1 , 9 claim 1 , and 10 (CDR1 claim 1 , CDR2 claim 1 , and CDR3 claim 1 , respectively) and a light chain variable region comprising complementarity determining regions consisting of the amino acid sequence shown in SEQ ID NOs: 11 claim 1 , 12 claim 1 , and 13 (CDR1 claim 1 , CDR2 claim 1 , and CDR3 claim 1 , ...

PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND/OR PREVENTION

The present invention provides a conjugate of an antibody or a fragment thereof linked to an immune activator, wherein the antibody or the fragment thereof has immunological reactivity with a CAPRIN-1 protein, and a pharmaceutical composition comprising the conjugate as an active ingredient for treatment and/or prevention of a cancer which is superior in antitumor activity to conventional antibodies or conjugates of an antibody and an immune activator. 1. A conjugate of an antibody or a fragment thereof linked to an immune activator , wherein the antibody or the fragment thereof has immunological reactivity with a CAPRIN-1 protein having an amino acid sequence represented by any of even-numbered SEQ ID NOs among SEQ ID NOs: 2 to 30 or an amino acid sequence having 80% or more sequence identity to the amino acid sequence.2. The conjugate according to claim 1 , wherein the antibody or the fragment thereof has immunological reactivity with a partial polypeptide of the CAPRIN-1 protein claim 1 , wherein the partial polypeptide has an amino acid sequence represented by any of SEQ ID NOs: 31 to 35 and 296 to 299 claim 1 , 308 claim 1 , and 309 or an amino acid sequence having 80% or more sequence identity to the amino acid sequence.3. The conjugate according to claim 1 , wherein the antibody is a monoclonal antibody or a polyclonal antibody.4. The conjugate according to claim 1 , wherein the antibody or the fragment thereof is any of the following (A) to (M):(A) an antibody or a fragment thereof, which comprises a heavy chain variable region comprising complementarity-determining regions of SEQ ID NOs: 36, 37, and 38 (CDR1, CDR2, and CDR3, respectively) and a light chain variable region comprising complementarity-determining regions of SEQ ID NOs: 40, 41, and 42 (CDR1, CDR2, and CDR3, respectively) and has immunological reactivity with the CAPRIN-1 protein,(B) an antibody or a fragment thereof, which comprises a heavy chain variable region comprising complementarity- ...

IMMUNITY INDUCTION AGENT

Provided is a novel immunity-inducing agent useful as a therapeutic and/or prophylactic agent for cancer. The immunity-inducing agent comprises as an effective ingredient(s) at least one polypeptide having immunity-inducing activity selected from the polypeptides (a), (b) and (c) below, and/or a recombinant vector(s) that comprise(s) a polynucleotide(s) encoding the at least one polypeptide, which recombinant vector(s) is/are capable of expressing the polypeptide(s) in vivo: (a) a polypeptide composed of not less than 7 consecutive amino acids in any one of the amino acid sequences of SEQ ID NOs:4, 2, 22 and 24 in SEQUENCE LISTING; (b) a polypeptide having a sequence identity of not less than 90% to the polypeptide (a) and composed of not less than 7 amino acids; and (c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof. 1. An immunity-inducing agent comprising as an effective ingredient(s) at least one polypeptide having immunity-inducing activity selected from the polypeptides (a) to (c) below , and/or a recombinant vector(s) that comprise(s) a polynucleotide(s) encoding said at least one polypeptide , said recombinant vector(s) being capable of expressing said polypeptide(s) in vivo:(a) a polypeptide composed of not less than 7 consecutive amino acids in any one of the amino acid sequences of SEQ ID NOs:4, 2, 22 and 24 in SEQUENCE LISTING;(b) a polypeptide having a sequence identity of not less than 85% to said polypeptide (a) and composed of not less than 7 amino acids; and(c) a polypeptide comprising said polypeptide (a) or (b) as a partial sequence thereof.2. The immunity-inducing agent according to claim 1 , wherein said polypeptide having immunity-inducing activity is a polypeptide having the amino acid sequence of SEQ ID NO:4 claim 1 , 2 claim 1 , 22 or 24 in SEQUENCE LISTING.3. The immunity-inducing agent according to claim 1 , which is an agent for treating antigen-presenting cells.4. The immunity-inducing agent according ...

PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PROPHYLAXIS OF CANCER

An object of the present invention is to prepare an antibody that targets CAPRIN-1 specifically expressed on the surface of cancer cells and is superior in antitumor activity to conventional antibodies and to provide use of the antibody as a therapeutic and/or preventive agent for cancer. The present invention provides use of an antibody targeting an identified cancer antigenic protein specifically expressed on the surface of cancer cells as a therapeutic and/or preventive agent for cancer, specifically, a pharmaceutical composition for treatment and/or prevention of cancer, comprising as an active ingredient an antibody or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein, the antibody or the fragment thereof comprising a heavy chain variable region comprising amino acid sequences represented by SEQ ID NOs: 5, 6, and 7 and a light chain variable region comprising amino acid sequences represented by SEQ ID NOs: 9, 10, and 11. 1. An antibody or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein , the antibody or the fragment thereof comprising a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 5 , 6 , and 7 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 9 , 10 , and 11.2. The antibody or the fragment thereof according to claim 1 , wherein the antibody is a human antibody claim 1 , a humanized antibody claim 1 , a chimeric antibody claim 1 , a single-chain antibody claim 1 , or a multispecific antibody.3. The antibody or the fragment thereof according to claim 1 , wherein the antibody or the fragment thereof is conjugated with an antitumor agent.4. A pharmaceutical composition for treatment and/or prevention of cancer claim 1 , comprising an antibody or a fragment thereof according to as an active ingredient.5. The pharmaceutical composition according to claim 4 , wherein the cancer is breast cancer claim 4 , kidney cancer ...

IMMUNITY-INDUCING AGENT

The present invention relates to a novel immunity-inducing agent for treatment and/or prevention of cancer. Specifically, the present invention relates to an immunity-inducing agent comprising, as an active ingredient, at least one polypeptide having immunity-inducing activity and selected from polypeptides derived from MRAP2 and modified forms thereof, or a recombinant vector comprising a polynucleotide encoding the polypeptide and capable of expressing the polypeptide in vivo, and a method for inducing immunity, comprising administering the immunity-inducing agent to a subject. 1. An immunity-inducing agent comprising , as an active ingredient , at least one polypeptide having immunity-inducing activity and selected from the group consisting of the following polypeptides (a) to (d) , or a recombinant vector comprising a polynucleotide encoding the polypeptide and capable of expressing said polypeptide in vivo:(a) a polypeptide consisting of 7 or more consecutive amino acids or a full-length sequence in the amino acid sequence represented by SEQ ID NO: 2, 4, 6, or 8 in the Sequence Listing;(b) a polypeptide consisting of an amino acid sequence obtained by deletion, substitution or addition of one or several amino acids in the amino acid sequence represented by SEQ ID NO: 2, 4, 6, or 8 in the Sequence Listing;(c) a polypeptide consisting of an amino acid sequence having a sequence identity of 90% or more with the amino acid sequence represented by SEQ ID NO: 2, 4, 6, or 8 in the Sequence Listing;(d) a polypeptide comprising any of the polypeptides (a) to (c) as a partial sequence.2. The immunity-inducing agent according to claim 1 , which is an agent for treating antigen-presenting cells.3. The immunity-inducing agent according to claim 1 , which is an active ingredient for a therapeutic and/or preventive agent for cancer.4. The immunity-inducing agent according to claim 3 , wherein the cancer is an MRAP2 expressing cancer.5. The immunity-inducing agent according to ...

IMMUNITY INDUCER

The present invention addresses the problem of finding a novel peptide useful as an active ingredient in an agent for treating or preventing cancer, and to provide the use of the polypeptide as an immune inducer. 1. An immune inducer comprising , as an active ingredient ,at least one polypeptide having an immune-inducing activity and selected from the group of polypeptides (a) or (b) below:(a) polypeptides consisting of 7 or more consecutive amino acids within the region of positions 34 to 50, positions 69 to 148, positions 178 to 195, positions 207 to 242, positions 247 to 280 and positions 296 to 332 in the amino acid sequence represented by SEQ ID NO: 2;(b) polypeptides comprising one to several amino acid deletions, substitutions, insertions or additions in the amino acid sequence of any one of the polypeptides (a); ora recombinant vector comprising at least one polynucleotide encoding any one of the polypeptides, and capable of expressing the polypeptide in vivo.2. The immune inducer according to claim 1 , wherein the polypeptide having an immune-inducing activity binds to an MHC class I molecule.3. The immune inducer according to claim 2 , wherein the polypeptide having an immune-inducing activity is any one of the polypeptides selected from the group of polypeptides (c) to (e) below:(c) polypeptides consisting of the amino acid sequences represented by SEQ ID NOs: 3 to 36;(d) polypeptides comprising one to several amino acid deletions, substitutions, insertions or additions in the amino acid sequence of any one of the polypeptides (c);(e) polypeptides each comprising as a partial sequence any one of the polypeptides (c) or (d).4. The immune inducer according to claim 1 , wherein the polypeptide having an immune-inducing activity binds to an MHC class II molecule.5. The immune inducer according to claim 4 , wherein the polypeptide having an immune-inducing activity is any one of the polypeptides selected from the group of polypeptides (f) to (h) below:(f) ...

PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER

An object of the present invention is to identify a cancer antigen protein specifically expressed on the surface of cancer cells and provide use of an antibody targeting the cancer antigen protein as a therapeutic and/or prophylactic agent for cancer. A pharmaceutical composition for treating and/or preventing cancer comprising an antibody or a fragment thereof having immunological reactivity with CSPG5 protein consisting of any one of amino acid sequences represented by SEQ ID NOs: 8, 4, 6, 10, and 12 and an amino acid sequence having an amino acid identity of 80% or more to the amino acid sequence, or a fragment thereof consisting of 7 or more consecutive amino acids, as an active ingredient. 1. A pharmaceutical composition for treating and/or preventing cancer , comprising an antibody or a fragment thereof having immunological reactivity with CSPG5 protein or a fragment thereof consisting of at least 7 or more consecutive amino acid residues , as an active ingredient.2. The pharmaceutical composition according to claim 1 , wherein the CSPG5 protein consists ofany one of amino acid sequences represented by SEQ ID NOs: 8, 4, 6, 10 and 12, oran amino acid sequence having an amino acid identity of 80% or more to the amino acid sequence.3. The pharmaceutical composition according to claim 1 , wherein the cancer is leukemia or malignant lymphoma.4. The pharmaceutical composition according to claim 1 , wherein the antibody is a monoclonal antibody or a polyclonal antibody.5. The pharmaceutical composition according to claim 1 , wherein the antibody is a human antibody claim 1 , a humanized antibody claim 1 , a chimeric antibody claim 1 , a single-chain antibody or a bispecific antibody. The present invention relates to novel medicinal use of an antibody against CSPG5 protein or a fragment thereof as e.g., a therapeutic and/or prophylactic agent for cancer.Cancer is a disease occupying the leading position of cause of death. Therapies presently employed are primarily ...

Immunity-inducing agent

This application provides an immunity-inducing agent comprising, as an active ingredient, at least one polypeptide having immunity-inducing activity and selected from (a) polypeptides consisting of amino acid sequences represented by SEQ ID NO: 8, 4, 6, 10, 12, 2 and 14, and polypeptides consisting of 7 or more consecutive amino acids in the amino acid sequences, (b) polypeptides having a sequence identity of 85% or more with the amino acid sequences represented by SEQ ID NO: 8, 4, 6, 10, 12, 2 and 14, and polypeptides consisting of 7 or more consecutive amino acids in the amino acid sequences, and (c) polypeptides comprising the polypeptides according to (a) or (b) as the partial sequences, or a recombinant vector comprising a polynucleotide encoding the polypeptide and capable of expressing the polypeptide in vivo.

IMMUNITY-INDUCING AGENT

The present application relates to a novel immunity-inducing agent for treatment and/or prevention of cancer. Specifically, the present application provides an immunity-inducing agent comprising, as an active ingredient, at least one polypeptide having immunity-inducing activity and selected from polypeptides derived from MCEMP1 and modified forms thereof, or a recombinant vector comprising a polynucleotide encoding the polypeptide and capable of expressing the polypeptide in vivo, and a method for inducing immunity, comprising administering the immunity-inducing agent to a subject. 1. An immunity-inducing agent comprising , as an active ingredient , at least one polypeptide having immunity-inducing activity and selected from any of the following polypeptides (a) to (d) , or a recombinant vector comprising a polynucleotide encoding the polypeptide and capable of expressing said polypeptide in vivo:(a) a polypeptide consisting of 7 or more consecutive amino acids or a full-length sequence in the amino acid sequence represented by SEQ ID NO: 2, 4, 6, or 8 in the Sequence Listing;(b) a polypeptide consisting of an amino acid sequence obtained by deletion, substitution or addition of one or several amino acids in the amino acid sequence represented by SEQ ID NO: 2, 4, 6, or 8 in the Sequence Listing;(c) a polypeptide consisting of an amino acid sequence having a sequence identity of 90% or more with the amino acid sequence represented by SEQ ID NO: 2, 4, 6, or 8 in the Sequence Listing;(d) a polypeptide comprising any of the polypeptides (a) to (c) as a partial sequence.2. The immunity-inducing agent according to claim 1 , which is an agent for treating antigen-presenting cells.3. The immunity-inducing agent according to claim 1 , which is an active ingredient for a therapeutic and/or preventive agent for cancer.4. The immunity-inducing agent according to claim 3 , wherein the cancer is an MCEMP1 expressing cancer.5. The immunity-inducing agent according to claim 3 , ...

PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PROPHYLAXIS OF CANCER

An object of the present invention is to prepare an antibody that targets CAPRIN-1 specifically expressed on the surface of cancer cells and is superior in antitumor activity to conventional antibodies and to provide use of the antibody as a therapeutic and/or preventive agent for cancer. The present invention provides use of an antibody targeting an identified cancer antigenic protein specifically expressed on the surface of cancer cells as a therapeutic and/or preventive agent for cancer, specifically, a pharmaceutical composition for treatment and/or prevention of cancer, comprising as an active ingredient an antibody or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein, the antibody or the fragment thereof comprising a heavy chain variable region comprising amino acid sequences represented by SEQ ID NOs: 5, 6, and 7 and a light chain variable region comprising amino acid sequences represented by SEQ ID NOs: 9, 10, and 11. 1. An antibody or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein , the antibody or the fragment thereof comprising a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 5 , 6 , and 7 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 9 , 10 , and 11.2. The antibody or the fragment thereof according to claim 1 , wherein the antibody is a human antibody claim 1 , a humanized antibody claim 1 , a chimeric antibody claim 1 , a single-chain antibody claim 1 , or a multispecific antibody.3. The antibody or the fragment thereof according to claim claim 1 , wherein the antibody or the fragment thereof is conjugated with an antitumor agent.4. A pharmaceutical composition for treatment and/or prevention of cancer claim 1 , comprising an antibody or a fragment thereof according to as an active ingredient.5. The pharmaceutical composition according to claim 4 , wherein the cancer is breast cancer claim 4 , kidney ...

METHOD FOR DETECTING PANCREATIC CANCER

This invention relates to a method for detecting pancreatic cancer using novel tumor markers. Specifically, the invention provides a method for detecting pancreatic cancer comprising measuring the presence or an amount of a polypeptide having an reactivity of binding via an antigen-antibody reaction to an antibody against CAPRIN-1 protein in a sample separated from a subject, and to a reagent or kit for detecting pancreatic cancer comprising a CAPRIN-1 protein or a fragment thereof, an antibody against the same, or a polynucleotide encoding the same. 1. A method for detecting pancreatic cancer , comprising measuring the presence or an amount of a polypeptide having a reactivity of specifically binding to an antibody against a CAPRIN-1 protein via an antigen-antibody reaction , or the presence or an amount of a nucleic acid encoding the polypeptide , in a sample separated from a subject.2. The method according to claim 1 , wherein the polypeptide to be measured is a CAPRIN-1 protein consisting of an amino acid sequence represented by any of the even-numbered SEQ ID NOs: 2 to 30 claim 1 , or a polypeptide consisting of an amino acid sequence having 85-90% or higher sequence identity with the CAPRIN-1 protein.3. The method according to claim 1 , wherein the subject is a human or a dog.4. The method according to claim 3 , wherein the subject is a dog and the polypeptide to be measured comprises an amino acid sequence represented by any of the even-numbered SEQ ID NOs: 2 to 30.5. The method according to claim 4 , wherein the subject is a dog and the polypeptide to be measured comprises the amino acid sequence represented by SEQ ID NO: 6 claim 4 , 8 claim 4 , 10 claim 4 , 12 claim 4 , or 14.6. The method according to claim 3 , wherein the subject is a human and the polypeptide to be measured comprises the amino acid sequence represented by SEQ ID NO: 2 or 4.7. The method according to claim 1 , wherein the presence or an amount of the polypeptide is determined by ...

IMMUNITY INDUCTION AGENT

Provided is a method for inducing immunity for therapy of a cancer(s). The method includes the step of administering to an individual with cancer at least one polypeptide selected from the polypeptides (a) or (b) below, and/or a recombinant vector(s) that comprise(s) a polynucleotide(s) encoding the at least one polypeptide, the recombinant vector(s) being capable of expressing the polypeptide(s) in vivo: (a) a polypeptide in any one of the amino acid sequences of SEQ ID NOs: 2, 4, 22, or 24; and (b) a polypeptide having a sequence identity of not less than 95% to the polypeptide (a). Further, an in vitro method for preparing an antigen-presenting cell is provided. The method includes the step of contacting the antigen-presenting cell with the at least one polypeptide selected from: (a) a polypeptide in any one of the amino acid sequences of SEQ ID NOs: 2, 4, 22, or 24; and (b) a polypeptide having a sequence identity of not less than 95% to the polypeptide (a). 1. A method for inducing immunity for therapy of a cancer(s) , said method comprising:administering to an individual with cancer at least one polypeptide selected from the polypeptides (a) or (b) below, and/or a recombinant vector(s) that comprise(s) a polynucleotide(s) encoding said at least one polypeptide, said recombinant vector(s) being capable of expressing said polypeptide(s) in vivo:(a) a polypeptide in any one of the amino acid sequences of SEQ ID NOs: 2, 4, 22, or 24; and(b) a polypeptide having a sequence identity of not less than 95% to said polypeptide (a).2. The method according to claim 1 , wherein said cancer(s) is/are a cancer(s) expressing SCD1.3. The method according to claim 1 , wherein said cancer(s) is/are breast cancer claim 1 , brain tumor perianal adenocarcinoma claim 1 , neuroblastoma claim 1 , mastocytoma claim 1 , liver cancer claim 1 , prostate cancer claim 1 , lung cancer claim 1 , thyroid cancer claim 1 , and/or leukemia.4. The method according to claim 1 , further ...

PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PROPHYLAXIS OF CANCER

This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof as a therapeutic and/or preventive agent for cancer. More specifically, the present invention provides an antibody, or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence shown by SEQ ID NO: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence, and a pharmaceutical composition for treatment and/or prevention of cancer comprising the same as an active ingredient. 1. An antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence shown by SEQ ID NO: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence.2. The antibody or the fragment thereof according to claim 1 , wherein the antibody or the fragment thereof has cytotoxic activity against a cancer cell expressing a CAPRIN-1 protein.3. The antibody or the fragment thereof according to claim 1 , wherein the antibody is a monoclonal antibody or a polyclonal antibody.4. The antibody or the fragment thereof according to claim 1 , wherein the antibody is a human antibody claim 1 , a humanized antibody claim 1 , a chimeric antibody claim 1 , a single-chain antibody claim 1 , or a multispecific antibody.5. The antibody or the fragment thereof according to claim 1 , which comprises a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 6 claim 1 , 7 claim 1 , and 8 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 10 claim 1 , 11 claim 1 , and 12 and has immunological reactivity with the CAPRIN-1 protein.6. The antibody or the fragment thereof according to claim 1 , which comprises a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: ...

PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER

A medicament for treatment and/or prevention of cancer, comprising an antibody or a fragment thereof having an immunological reactivity with a CAPRIN-1 protein, and imiquimod together or separately in combination can treat and/or prevent cancer specifically expressing CAPRIN-1 protein on a cell surface. 1. A medicament for treatment and/or prevention of cancer , comprising an antibody or a fragment thereof having an immunological reactivity with a CAPRIN-1 protein , and imiquimod together or separately in combination.2. The medicament according to claim 1 , wherein the antibody or the fragment has immunological reactivity with CAPRIN-1 protein having an amino acid sequence shown in any one of the even numbered SEQ ID NOs: 2 to 30 claim 1 , or an amino acid sequence having 80% or more sequence identity with the amino acid sequence.3. The medicament according to claim 1 , wherein the antibody or the fragment thereof has an immunological reactivity with an extracellular region of a CAPRIN-1 protein present on a cancer cell surface.4. The medicament according to claim 1 , wherein the antibody or the fragment thereof has an immunological reactivity with a partial polypeptide of CAPRIN-1 protein claim 1 , the partial polypeptide having an amino acid sequence represented by any one of SEQ ID NOs: 31 to 35 claim 1 , 296 to 299 claim 1 , 308 and 309 claim 1 , or an amino acid sequence having 80% or more sequence identity with the amino acid sequence.5. The medicament according to claim 1 , wherein the antibody is a monoclonal antibody or a polyclonal antibody.6. The medicament according to claim 1 , wherein the antibody or a fragment thereof is any one of the following (A) to (M):(A) an antibody or a fragment comprising a heavy-chain variable region comprising complementarity determining regions of SEQ ID NOs: 36, 37 and 38 (CDR1, CDR2 and CDR3, respectively) and a light-chain variable region comprising complementarity determining regions of SEQ ID NOs: 40, 41 and 42 (CDR1, ...

PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCERS

An object of the present invention is to identify cancer antigen proteins specifically expressed on the surface of cancer cells and to provide a use of antibodies targeting such proteins as therapeutic and/or preventive agents for cancer. The present invention relates to, for example, a pharmaceutical composition for treatment and/or prevention of a cancer, which comprises, as an active ingredient, an antibody or fragment thereof having an immunological reactivity with an MCEMP1 protein having an amino acid sequence shown in any one of the even numbered SEQ ID NOS: 2 to 8 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence, or with a fragment of the MCEMP1 protein comprising 7 or more consecutive amino acids. 1. A pharmaceutical composition for treatment and/or prevention of a cancer , which comprises , as an active ingredient , an antibody or fragment thereof having an immunological reactivity with an MCEMP1 protein having the amino acid sequence shown in SEQ ID NO: 2 , 4 , 6 , or 8 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence , or with a fragment of the MCEMP1 protein comprising 7 or more consecutive amino acids.2. The pharmaceutical composition according to claim 1 , which comprises claim 1 , as an active ingredient claim 1 , an antibody or fragment thereof having an immunological reactivity with a polypeptide comprising an extracellular region portion of the MCEMP1 protein claim 1 , the polypeptide being a polypeptide consisting of 7 or more consecutive amino acids of the amino acid sequence shown in SEQ ID NO: 10 claim 1 , 12 claim 1 , 14 claim 1 , or 16 claim 1 , or a polypeptide consisting of an amino acid sequence having 80% or more sequence identity with the amino acid sequence.3. The pharmaceutical composition according to claim 1 , wherein the cancer is a cancer expressing MCEMP1 on a cell surface.4. The pharmaceutical composition according to claim 1 , wherein the ...

PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PROPHYLAXIS OF CANCER

It is intended to identify a cancer antigenic protein specifically expressed on the surface of cancer cells and to provide an antibody targeting the antigenic protein and use of the antibody as a therapeutic and/or preventive agent for cancer. The present invention provides an antibody or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein, the antibody comprising a heavy chain variable region comprising amino acid sequences of SEQ ID NOs: 5, 6, and 7 and a light chain variable region comprising amino acid sequences of SEQ ID NOs: 9, 10, and 11, and a pharmaceutical composition for treatment and/or prevention of cancer, comprising this antibody or fragment as an active ingredient. 1. An antibody or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein , the antibody or the fragment thereof comprising a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 5 , 6 , and 7 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 9 , 10 , and 11.2. The antibody or the fragment thereof according to claim 1 , wherein the antibody is a human antibody claim 1 , a humanized antibody claim 1 , a chimeric antibody claim 1 , a single-chain antibody claim 1 , or a multispecific antibody.3. The antibody or the fragment thereof according to claim 1 , wherein the antibody or the fragment thereof is conjugated with an antitumor agent.4. A pharmaceutical composition for treatment and/or prevention of cancer claim 1 , comprising an antibody or a fragment thereof according to as an active ingredient.5. The pharmaceutical composition according to claim 4 , wherein the cancer is breast cancer claim 4 , kidney cancer claim 4 , pancreatic cancer claim 4 , large bowel cancer claim 4 , lung cancer claim 4 , brain tumor claim 4 , gastric cancer claim 4 , uterine cervix cancer claim 4 , ovary cancer claim 4 , prostate cancer claim 4 , urinary bladder cancer claim 4 , ...

PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCERS

The present invention relates to a pharmaceutical composition for treatment and/or prevention of a cancer, which comprises, as an active ingredient, an antibody or fragment thereof having an immunological reactivity with an MRAP2 protein having the amino acid sequence shown in SEQ ID NO: 2, 4, 6, or 8 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence, or with a fragment of the MRAP2 protein comprising 7 or more consecutive amino acids. 1. A pharmaceutical composition for treatment and/or prevention of a cancer , which comprises , as an active ingredient , an antibody or fragment thereof having an immunological reactivity with an MRAP2 protein having the amino acid sequence shown in SEQ ID NO: 2 , 4 , 6 , or 8 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence , or with a fragment of the MRAP2 protein comprising 7 or more consecutive amino acids.2. The pharmaceutical composition according to claim 1 , which comprises claim 1 , as an active ingredient claim 1 , an antibody or fragment thereof having an immunological reactivity with a partial polypeptide of the MRAP2 protein claim 1 , the partial polypeptide being a polypeptide consisting of 7 or more consecutive amino acids of the amino acid sequence shown in any one of the even numbered SEQ ID NOS: 10 to 24 claim 1 , or a polypeptide consisting of an amino acid sequence having 80% or more sequence identity with the amino acid sequence.3. The pharmaceutical composition according to claim 1 , wherein the cancer is a cancer expressing MRAP2 on a cell surface.4. The pharmaceutical composition according to claim 1 , wherein the cancer is selected from the group consisting of leukemia claim 1 , malignant lymphoma claim 1 , lung cancer claim 1 , brain tumor claim 1 , colorectal cancer claim 1 , melanoma claim 1 , neuroblastoma claim 1 , pancreatic cancer claim 1 , gastric cancer claim 1 , liver cancer claim 1 , ovary cancer claim 1 , ...

PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PROPHYLAXIS OF CANCER

This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof as a therapeutic and/or preventive agent for cancer. More specifically, the present invention provides an antibody, or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein, the antibody comprising a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 5, 6, and 7 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 9, 10, and 11, and a pharmaceutical composition for treatment and/or prevention of cancer, comprising the same as an active ingredient. 1. An antibody or a fragment thereof , wherein the antibody or the fragment thereof have immunological reactivity with a CAPRIN-1 protein and comprise a heavy chain variable region comprising complementarity determining regions of SEQ ID NOs: 5 , 6 , and 7 and a light chain variable region comprising complementarity determining regions of SEQ ID NOs: 9 , 10 , and 11.2. The antibody or the fragment thereof according to claim 1 , wherein the antibody is a human antibody claim 1 , a humanized antibody claim 1 , a chimeric antibody claim 1 , a single-chain antibody claim 1 , or a multispecific antibody.3. The antibody or the fragment thereof according to claim 1 , wherein the antibody or the fragment thereof is conjugated with an antitumor agent.4. A pharmaceutical composition for treatment and/or prevention of cancer claim 1 , comprising the antibody or the fragment thereof according to as an active ingredient.5. The pharmaceutical composition according to claim 4 , wherein the cancer is breast cancer claim 4 , kidney cancer claim 4 , pancreatic cancer claim 4 , colorectal cancer claim 4 , lung cancer claim 4 , brain tumor claim 4 , gastric cancer claim 4 , uterine cervix cancer claim 4 , ovary cancer claim 4 , prostate cancer claim 4 , urinary bladder cancer claim 4 , esophageal ...

IMMUNITY-INDUCING AGENT

An immunity-inducing agent comprising as an effective ingredient(s) a polypeptide(s) selected from the polypeptides: (a) a polypeptide consisting essentially of not less than 7 consecutive amino acids in any one of the amino acid sequences shown in SEQ ID NOs:2, 4, 6, 8, 10, 12 and 44 in SEQUENCE LISTING; (b) a polypeptide having a sequence identity of not less than 90% with the polypeptide (a) and consisting essentially of not less than 7 amino acids; and (c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof; which polypeptide(s) has/have an immunity-inducing activity/activities, or as an effective ingredient(s) a recombinant vector(s) which comprise(s) a polynucleotide(s) encoding the polypeptide(s) and is/are capable of expressing the polypeptide(s) in vivo, is useful as a therapeutic and/or prophylactic agent for cancer, and/or the like. 1. An immunity-inducing agent comprising as an effective ingredient(s) at leastone polypeptide selected from the polypeptides (a) to (c) below, said polypeptide(s) having an immunity-inducing activity/activities, or as an effective ingredient(s) a recombinant vector(s) which comprise(s) a polynucleotide(s) encoding said polypeptide(s) and is/are capable of expressing said polypeptide(s) in vivo:(a) a polypeptide consisting essentially of not less than 7 consecutive amino acids in any one of the amino acid sequences shown in SEQ ID NOs:2, 4, 6, 8, 10, 12 and 44;(b) a polypeptide having a sequence identity of not less than 90% with said polypeptide (a) and consisting essentially of not less than 7 amino acids; and(c) a polypeptide comprising said polypeptide (a) or (b) as a partial sequence thereof.2. The immunity-inducing agent according to claim 1 , wherein said polypeptide(b) has a sequence identity of not less than 95% with said polypeptide (a).3. The immunity-inducing agent according to claim 1 , wherein each of saidpolypeptide(s) having an immunity-inducing activity/activities is a polypeptide ...

Immunity-inducing agent

This application provides an immunity-inducing agent comprising, as an active ingredient, at least one polypeptide having immunity-inducing activity and selected from (a) polypeptides consisting of amino acid sequences represented by SEQ ID NO: 8, 4, 6, 10, 12, 2 and 14, and polypeptides consisting of 7 or more consecutive amino acids in the amino acid sequences, (b) polypeptides having a sequence identity of 85% or more with the amino acid sequences represented by SEQ ID NO: 8, 4, 6, 10, 12, 2 and 14, and polypeptides consisting of 7 or more consecutive amino acids in the amino acid sequences, and (c) polypeptides comprising the polypeptides according to (a) or (b) as the partial sequences, or a recombinant vector comprising a polynucleotide encoding the polypeptide and capable of expressing the polypeptide in vivo.

PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF CANCERS

The present invention relates to a pharmaceutical composition for treatment and/or prevention of cancer, which comprises, as an active ingredient, an antibody or fragment thereof having an immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising 7 or more consecutive amino acids. 1. A method of preparing an antibody , comprising:administering a CAPRIN-1 protein, which has an amino acid sequence shown in any one of even-numbered SEQ ID NOs: 2 to 30, or a polypeptide fragment thereof, to a mammal to be immunized, andpurifying the resultant antibodies to obtain the antibody that specifically binds the CAPRIN-1 protein or a polypeptide fragment thereof expressed on the cell surface of a cancer and has an antitumor activity.2. The method according to claim 1 , wherein the antitumor activity is an antibody-dependent cell-mediated cytotoxicity (ADCC) activity of the antibody.3. The method according to claim 1 , wherein the antibody is a monoclonal antibody or polyclonal antibody.4. The method according to claim 1 , wherein the antibody is a human antibody claim 1 , a humanized antibody claim 1 , a chimeric antibody claim 1 , a single-chain antibody claim 1 , or a bispecific antibody.5. The method according to claim 1 , further comprising separating spleen cells from the immunized mammal and fusing the separated spleen cells with mammalian myeloma cells to obtain a hybridoma producing the antibody.6. The method according to claim 5 , further comprising cloning DNA encoding an antibody from the hybridoma to obtain a clone for the antibody claim 5 , incorporating the clone into a vector claim 5 , and introducing the vector into a host cell to produce a recombinant antibody.7. The method according to claim 6 , wherein the cloned DNA comprises DNA encoding a heavy chain variable region and a light chain variable region of the antibody.8. The method according to claim 1 , further comprising preparing an antigen-binding fragment from the antibody claim 1 ...

METHOD FOR DETECTING CANCER

This invention provides: a method for detecting a cancer, comprising measuring the expression of a polypeptide having binding reactivity through antigen-antibody reaction with an antibody against CAPRIN-1 having the amino acid sequence shown in any even-numbered SEQ ID NO of SEQ ID NOs: 2 to 30 in the Sequence Listing in a biological sample; a method for detecting a cancer which involves determining the presence and the amount of CAPRIN-1 in a sample of a cancer patient in order to determine the administration of a CAPRIN-1-targeting drug to the cancer patient; and a drug and a kit for the diagnosis of a cancer, comprising an anti-CAPRIN-1 antibody. 1. A method for detecting a cancer , comprising measuring the expression level of CAPRIN-1 in a biological sample through antigen-antibody reaction using an antibody having immunological reactivity with a polypeptide having the amino acid sequence shown in SEQ ID NO: 66 , or an antigen-binding fragment thereof.2. The method for detecting a cancer according to claim 1 , wherein the CAPRIN-1 to be measured is:(a) a polypeptide having the amino acid sequence shown in any even-numbered SEQ ID NO of SEQ ID NOs: 2 to 30 in the Sequence Listing, or(b) a polypeptide having 85% or higher sequence identity to the polypeptide having the amino acid sequence shown in any even-numbered SEQ ID NO of SEQ ID NOs: 2 to 30 in the Sequence Listing.3. The method for detecting a cancer according to claim 1 , wherein the biological sample is derived from a human claim 1 , a dog claim 1 , or a cat.4. The method for detecting a cancer according to claim 1 , wherein the biological sample is derived from a dog claim 1 , and the CAPRIN-1 to be measured has the amino acid sequence shown in SEQ ID NO: 6 claim 1 , 8 claim 1 , 10 claim 1 , 12 claim 1 , or 14.5. The method for detecting a cancer according to claim 1 , wherein the biological sample is derived from a human claim 1 , and the CAPRIN-1 to be measured has the amino acid sequence shown in SEQ ...

METHOD FOR DETECTING CANCER

This invention provides: a method for detecting a cancer, comprising measuring the expression of a polypeptide having binding reactivity through antigen-antibody reaction with an antibody against CAPRIN-1 having an amino acid sequence shown in any even-numbered SEQ ID NO shown in SEQ ID NOs: 2 to 30 in the Sequence Listing in a biological sample; a method for detecting a cancer which involves determining the presence and the amount of CAPRIN-1 in a sample of a cancer patient in order to determine the administration of a therapeutic drug targeting CAPRIN-1 to the cancer patient; and a drug and a kit for the diagnosis of a cancer, comprising an anti-CAPRIN-1 antibody. 1. A method for detecting a cancer , comprising measuring the expression level of CAPRIN-1 in a biological sample through antigen-antibody reaction using an antibody having immunological reactivity with a polypeptide having the amino acid sequence shown in SEQ ID NO: 63 , or an antigen-binding fragment thereof.2. The method for detecting a cancer according to claim 1 , wherein CAPRIN-1 to be measured is(a) a polypeptide having the amino acid sequence shown in any even-numbered SEQ ID NO shown in SEQ ID NOs: 2 to 30 in the Sequence Listing, or(b) a polypeptide having 85% or higher sequence identity to the polypeptide.3. The method for detecting a cancer according to claim 1 , wherein the biological sample is derived from a human claim 1 , a dog claim 1 , or a cat.4. The method for detecting a cancer according to claim 1 , wherein the biological sample is derived from a dog claim 1 , and CAPRIN-1 to be measured has an amino acid sequence shown in SEQ ID NO: 6 claim 1 , 8 claim 1 , 10 claim 1 , 12 claim 1 , or 14.5. The method for detecting a cancer according to claim 1 , wherein the biological sample is derived from a human claim 1 , and CAPRIN-1 to be measured has an amino acid sequence shown in SEQ ID NO: 2 or 4.6. The method for detecting a cancer according to claim 1 , wherein a measured CAPRIN-1 ...

PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF CANCERS

The present invention relates to a pharmaceutical composition for treatment and/or prevention of cancer, which comprises, as an active ingredient, an antibody or fragment thereof having an immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising 7 or more consecutive amino acids. 1. An antibody having an immunological reactivity with a polypeptide having the amino acid sequence shown in SEQ ID NO: 37 or SEQ ID NO: 136 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence.2. The antibody according to claim 1 , which is a human antibody claim 1 , a humanized antibody claim 1 , a chimeric antibody claim 1 , a single-chain antibody claim 1 , or a bispecific antibody.3. A pharmaceutical composition for treatment and/or prevention of cancer claim 1 , which comprises claim 1 , as an active ingredient claim 1 , the antibody according to or a fragment thereof. This application is a Divisional of copending application Ser. No. 13/057,709, filed on Feb. 4, 2011, which was filed as PCT International Application No. PCT/JP2009/063882 on Aug. 5, 2009, and to Patent Applications No. JP 2009-087285 filed in Japan on Mar. 31, 2009 and No. JP 2008-201928 filed in Japan on Aug. 5, 2008, all of which are hereby expressly incorporated by reference into the present application.The present invention relates to a novel medical use of antibodies to CAPRIN-1 or fragments thereof as, for example, therapeutic and/or preventive agents for cancer.Cancer is the leading cause of death. Treatment currently performed for cancer is mainly surgical therapy, which can be combined with radiation therapy or chemotherapy. In spite of development of new surgical methods and discovery of new anti-cancer agents in recent years, treatment results of cancers are not greatly improved at present except for some cancers. Through a recent progress of molecular biology and cancer immunology, antibodies that are specifically reactive with cancers, cancer ...

IMMUNE INDUCER

An object of the present invention is to discover a novel peptide useful as an active ingredient in an agent for treating or preventing cancer, and to provide the use of the polypeptide as an immune inducer. The immune inducer containing as an active ingredient: (a) a polypeptide consisting of any one of the amino acid sequences represented by SEQ ID NOs: 35 to 67; or (b) a polypeptide comprising one to several amino acid deletions, substitutions and/or additions in the amino acid sequence of the polypeptide (a); is useful as an agent for treating or preventing cancer, etc. 1. An immune inducer comprising , as an active ingredient , the following (i) or (ii): (a) polypeptides consisting of 7 or more consecutive amino acids within the region of positions 24 to 97, positions 113 to 132, positions 134 to 197, positions 204 to 225, positions 265 to 332, positions 378 to 463, positions 472 to 498, positions 533 to 567, positions 613 to 643, positions 671 to 735, positions 737 to 780, positions 792 to 830, positions 832 to 899, positions 920 to 943, positions 946 to 993, positions 1029 to 1069 and positions 1074 to 1215 in the amino acid sequence represented by SEQ ID NO: 2;', '(b) polypeptides comprising one to several amino acid deletions, substitutions and/or additions in the amino acid sequence of any one of the polypeptides (a);, '(i) at least one polypeptide having an immune-inducing activity and selected from the group of polypeptides (a) or (b) below(ii) a recombinant vector comprising at least one polynucleotide encoding any one of the polypeptides, and capable of expressing the polypeptide in vivo.2. The immune inducer according to claim 1 , wherein the polypeptide (i) binds to a MHC class I molecule.3. The immune inducer according to claim 2 , wherein the polypeptide (i) is any one of the polypeptide selected from the group of polypeptides (c) to (e) below:(c) polypeptides consisting of the amino acid sequences represented by SEQ ID NOs: 3 to 34;(d) ...

PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF LIVER CANCER

Provided is an antibody effective for treatment and/or prevention of liver cancer. A pharmaceutical composition for treatment and/or prevention of liver cancer contains as an active ingredient an antibody or a fragment thereof having immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising at least seven consecutive amino acid residues of the amino acid sequence of the protein. 1. A pharmaceutical composition for treating and/or preventing liver cancer , comprising , as an active ingredient , an antibody or a fragment thereof having immunological reactivity with a CAPRIN-1 protein comprising an amino acid sequence set forth in any of even sequence numbers from SEQ ID NOs: 2 to 30 or an amino acid sequence having a sequence identity of 80% or more to the amino acid sequence , or a fragment of the CAPRIN-1 protein comprising at least seven consecutive amino acid residues of the amino acid sequence of the protein.2. The pharmaceutical composition according to claim 1 , wherein the fragment of the CAPRIN-1 protein comprises at least seven consecutive amino acid residues in the region of amino acid residue positions from 233 to 343 claim 1 , amino acid residue positions from 512 to the C-terminal claim 1 , or amino acid residue positions from 50 to 98 of the amino acid sequence set forth in any of even sequence numbers from SEQ ID NOs: 2 to 30 excluding SEQ ID NOs: 6 and 18.3. The pharmaceutical composition according to claim 1 , wherein the fragment of the CAPRIN-1 protein comprises at least seven consecutive amino acid residues in an amino acid sequence set forth in SEQ ID NO: 267 claim 1 , SEQ ID NO: 429 claim 1 , SEQ ID NO: 428 claim 1 , SEQ ID NO: 273 claim 1 , SEQ ID NO: 266 claim 1 , SEQ ID NO: 270 claim 1 , SEQ ID NO: 272 claim 1 , SEQ ID NO: 269 claim 1 , SEQ ID NO: 430 claim 1 , SEQ ID NO: 431 claim 1 , or SEQ ID NO: 432 or in an amino acid sequence having a sequence identity of 80% or more to any of the amino acid sequences.4. The ...

PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PANCREATIC CANCER

This invention relates to a pharmaceutical composition for treatment and/or prevention of pancreatic cancer, comprising as an active ingredient an antibody or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising 7 to 12 or more consecutive amino acid residues. 1. A pharmaceutical composition for treatment and/or prevention of pancreatic cancer , comprising , as an active ingredient , an antibody or a fragment thereof which specifically has immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising 7 to 12 or more consecutive amino acid residues.2. The pharmaceutical composition according to claim 1 , wherein the CAPRIN-1 protein has an amino acid sequence represented by any of even-numbered SEQ ID NOs: 2 to 30 claim 1 , or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence.3. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition comprises claim 1 , as an active ingredient claim 1 , an antibody or a fragment thereof which has immunological reactivity with the fragment of the CAPRIN-1 protein claim 1 , the fragment being a polypeptide consisting of 7 or more consecutive amino acid residues in a region of amino acid residue numbers 50 to 98 claim 1 , a region of amino acid residue numbers 233 to 343 claim 1 , or a region of amino acid residue number 527 to the C terminus claim 1 , of an amino acid sequence represented by any of even-numbered SEQ ID NOs: 2 to 30 except for SEQ ID NOs: 6 and 18 claim 1 , or a polypeptide comprising the polypeptide as a partial sequence.4. The pharmaceutical composition according to claim 1 , wherein the antibody or the fragment thereof is an antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide having an amino acid sequence represented by SEQ ID NO: 273 claim 1 , 266 claim 1 , 270 claim 1 , 272 claim 1 , or 269 claim 1 , or an amino ...

Pharmaceutical composition for treatment and/or prevention of cancer

According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen protein as an agent for treating and/or preventing a cancer is provided. Specifically, the present invention provides a pharmaceutical composition for treating and/or preventing a cancer, which comprises an antibody or a fragment thereof as an active ingredient having immunological reactivity with a partial polypeptide of CAPRIN-1, wherein CAPRIN-1 is represented by any of the even-numbered sequences of SEQ ID NOS: 2 to 30, and wherein the partial polypeptide comprises the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence.

PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF CANCER

An antibody or a fragment thereof having immunoreactivity to a polypeptide comprising not less than 7 continuous amino acids in the CD179b protein, which was identified as a cancer antigen protein specifically expressed on the surfaces of cancer cells, can be used as a pharmaceutical composition for therapy and/or prophylaxis of cancer. 1. A method for therapy of human leukemia expressing CD179b protein comprising administering to a human patient in need thereof an effective amount of an antibody , said antibody having immunoreactivity to a CD179b protein having the amino acid sequence shown in SEQ ID NO:3 ,wherein the antibody has an Fc effector domain capable of mediating antibody-dependent cell-mediated cytotoxicity (ADCC) by effector cells and/or complement-dependent cytotoxicity (CDC) against CD179b-expressing cells and/or which is conjugated to a cytotoxic moiety capable of inhibiting the proliferation and/or survival of the leukemia cells, andwherein said leukemia is chronic lymphocyte leukemia.2. The method according to claim 1 , further comprising administering a pharmaceutically acceptable carrier.3. The method according to claim 1 , wherein said antibody is a human antibody claim 1 , humanized antibody claim 1 , chimeric antibody claim 1 , single-chain antibody or bispecific antibody.4. The method according to claim 1 , wherein said antibody comprises a heavy chain variable region having the amino acid sequences shown in SEQ ID NOs: 102 claim 1 , 103 claim 1 , or 104 and a light chain variable region having the amino acid sequences shown in SEQ ID NOs: 106 claim 1 , 107 or 108 claim 1 , said antibody having immunoreactivity to a CD 179b protein. This application is a divisional application of U.S. patent application Ser. No. 13/002,636, filed Feb. 15, 2011, which is a U.S. National Phase Application under 35 U.S.C. 371 of Intentional Patent Application No. PCT/JP2009/062573 filed Jul. 10, 2009, which claims priority to Japanese Application Serial No. 2008 ...

Pharmaceutical composition for treatment and/or prevention of gallbladder cancer

Provided is an antibody effective for treatment and/or prevention of gallbladder cancer. A pharmaceutical composition for treatment and/or prevention of gallbladder cancer contains as an active ingredient an antibody or a fragment thereof having immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising at least seven consecutive amino acid residues of the amino acid sequence of the protein.

Pharmaceutical composition for treatment and/or prevention of cancer

It is intended to provide a CAPRIN-1-targeting antibody superior in antitumor activity to conventional antibodies, and use thereof as a therapeutic and/or preventive agent for a cancer. The present invention provides an antibody targeting a CAPRIN-1 polypeptide specifically expressed on the surface of cancer cells, and use of the antibody as a therapeutic and/or preventive agent for a cancer. The present invention provides an antibody which comprises a heavy chain variable region comprising complementarity-determining regions of SEQ ID NOs: 1, 2, and 3 and a light chain variable region comprising complementarity-determining regions of SEQ ID NOs: 4, 5, and 6 and has immunological reactivity with a CAPRIN-1 protein, or a fragment thereof, and a pharmaceutical composition for the treatment and/or prevention of a cancer, comprising this antibody or fragment as an active ingredient.

PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF CANCERS

The present invention relates to a pharmaceutical composition for treatment and/or prevention of cancer, which comprises, as an active ingredient, an antibody or fragment thereof having an immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising 7 or more consecutive amino acids. 1. An antibody or antigen-binding fragment thereof that binds a CAPRIN-1 protein which has the amino acid sequence shown in any one of the even numbered SEQ ID NOs: 2 to 30 , wherein the antibody or fragment specifically binds the CAPRIN-1 protein expressed on the cell surface of the cancer.2. The antibody according to claim 1 , which has an antibody-dependent cell-mediated cytotoxicity (ADCC) activity of the antibody.3. The antibody according to claim 1 , which is a monoclonal antibody or polyclonal antibody.4. The antibody according to claim 1 , which is a human antibody claim 1 , a humanized antibody claim 1 , a chimeric antibody claim 1 , a single-chain antibody claim 1 , or a bispecific antibody. This application is a Divisional of copending application Ser. No. 15/092,469, filed on Apr. 6, 2016, which is a Divisional of application Ser. No. 13/057,709, filed on Feb. 4, 2011, patented as U.S. Pat. No. 9,416,192, on Aug. 16, 2016, which was filed as PCT International Application No. PCT/JP2009/063882 on Aug. 5, 2009, and to Patent Applications No. JP 2009-087285 filed in Japan on Mar. 31, 2009 and No. JP 2008-201928 filed in Japan on Aug. 5, 2008, all of which are hereby expressly incorporated by reference into the present application.The present invention relates to a novel medical use of antibodies to CAPRIN-1 or fragments thereof as, for example, therapeutic and/or preventive agents for cancer.Cancer is the leading cause of death. Treatment currently performed for cancer is mainly surgical therapy, which can be combined with radiation therapy or chemotherapy. In spite of development of new surgical methods and discovery of new anti-cancer agents in recent ...

Production of useful protein

(57)【要約】 （修正有） 【課題】 組換えバキュロウイルスによる有用蛋白質の 製造方法を提供する。 【解決手段】 組換えバキュロウイルスを昆虫培養細胞 又はカイコ幼虫にイヌインターフェロン−γ、ネコイン ターフェロン−ω、イヌインターロイキン−１２又はヒ トインターフェロン等の有用蛋白質を製造させる際に、 上記昆虫培養細胞の培養ヒ清、又はカイコ幼虫の体液に エチレンジアミン四酢酸二ナトリウム等の金属キレート 剤を添加したうえで、流通式で紫外線を照射することに より組換えバキュロウイルスの不活性化と目的蛋白質の 精製を容易にする。

Pharmaceutical composition for the treatment and prevention of cancer

Un anticuerpo para su uso en un metodo de terapia y/o profilaxis del cancer, teniendo dicho anticuerpo inmunorreactividad a una proteina CD179b que tiene la secuencia de aminoacidos mostrada en la SEQ ID NO: 3, en donde el anticuerpo es capaz de mediar la citotoxicidad mediada por celulas dependiente de anticuerpos (ADCC) por celulas efectoras y la citotoxicidad dependiente del complemento (CDC) contra celulas que expresan CD179.

pharmaceutical compositions, antibodies and uses of an antibody or a fragment thereof.

COMPOSIÇÕES FARMACÊUTICAS, ANTICORPOS E USOS DE UM ANTICORPO OU UM FRAGMENTO DO MESMO. A presente invenção refere-se a uma composição farmacêutica para tratamento e/ou prevenção de câncer, que compreende, como um ingrediente ativo, um anticorpo ou um fragmento do mesmo que tem uma reatividade imunológica a uma proteína CAPRIN-I ou um fragmento do mesmo que compreende 7 ou mais aminoácidos consecutivos. PHARMACEUTICAL COMPOSITIONS, ANTIBODIES AND USES OF AN ANTIBODY OR A FRAGMENT OF THE SAME. The present invention relates to a pharmaceutical composition for treatment and / or prevention of cancer, which comprises, as an active ingredient, an antibody or a fragment thereof which has an immunological reactivity to a CAPRIN-I protein or a fragment thereof comprising 7 or more consecutive amino acids.

Pharmaceutical composition for the treatment and / or prevention of cancer

Un anticuerpo o un fragmento del mismo, que (i) tiene reactividad inmunológica con un polipéptido que consiste en la secuencia de aminoácidos representada por la SEC ID Nº 37 o una secuencia de aminoácidos que tiene un 80 % o más de identidad de secuencia con la secuencia de aminoácidos de la SEC ID Nº 37; o (ii) reconoce un fragmento que consiste en 7 a 12 aminoácidos en la secuencia de aminoácidos representada por la SEC ID Nº 37 o una secuencia de aminoácidos que tiene un 80 % o más de identidad de secuencia con la secuencia de aminoácidos de la SEC ID Nº 37. An antibody or fragment thereof, which (i) has immunological reactivity with a polypeptide consisting of the amino acid sequence represented by SEQ ID No. 37 or an amino acid sequence that has 80% or more sequence identity with the amino acid sequence of SEQ ID NO: 37; or (ii) recognizes a fragment consisting of 7 to 12 amino acids in the amino acid sequence represented by SEQ ID No. 37 or an amino acid sequence that has 80% or more sequence identity with the amino acid sequence of SEC ID No. 37.

Pharmaceutical composition for treating and/or preventing cancer

Disclosed is use of an antibody, which targets an identified cancer antigen protein specifically expressed on the surface of cancer cells, as a therapeutic and/or prophylactic agent for cancer. Specifically disclosed is a medicinal composition for treating and/or preventing cancer characterized by containing, as the active ingredient, an antibody, which comprises a heavy chain variable region comprising SEQ ID NOS:39, 40 and 41 and a light chain variable region comprising SEQ ID NOS:43, 44 and 45 and is immunologically reactive with CAPRIN-1 protein, or a fragment of said antibody.

Pharmaceutical composition for treating cancer using a monoclonal antibody having immunological reactivity with CAPRIN-1

According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen protein as an agent for treating and/or preventing a cancer is provided. Specifically, the present invention provides a pharmaceutical composition for treating and/or preventing a cancer, which comprises an antibody or a fragment thereof as an active ingredient having immunological reactivity to a partial polypeptide of CAPRIN-1, which is represented by any of even-numbered sequences of SEQ ID NOS: 2 to 30, wherein the polypeptide has the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence.

PHARMACEUTICAL COMPOSITION CONTAINING ANTI CAPRIN-1 ANTIBODIES FOR TREATMENT AND / OR PREVENTION OF CANCER

Medicinal composition for treating and/or preventing cancer

Pharmaceutical composition for treatment and/or prevention of liver cancer

Provided is antibody effective for the treatment and/or prevention of liver cancer. A pharmaceutical composition for the treatment and/or prevention of liver cancer, including as an effective component thereof: an antibody having immunological reactivity to a CAPRIN-1 protein or a fragment thereof including at least seven continuous amino acid resides in an amino acid array of said protein; or a fragment thereof.

Pharmaceutical composition for treatment and/or prevention of cancer

Pharmaceutical composition for cancer treatment and/or prevention.

La presente invención proporciona un conjugado de un anticuerpo o un fragmento del mismo unido a un activador inmunitario, en donde el anticuerpo o fragmento del mismo tiene reactividad inmunológica con una proteína CAPRIN-1, y una composición farmacéutica que comprende el conjugado como ingrediente activo para el tratamiento y/o prevención de un cáncer que sea superior en actividad antitumoral a los anticuerpos convencionales o conjugados de un anticuerpo y un activador inmunitario.

DRUG FOR THE TREATMENT AND/OR PREVENTION OF CANCER, AGENTS THAT INCREASE THE EFFICACY OF A DRUG AND METHOD FOR THE TREATMENT AND/OR PREVENTION OF CANCER

MEDICAMENTO PARA O TRATAMENTO E/OU PREVENÇÃO DO CÂNCER, AGENTES QUE AUMENTAM A EFICÁCIA DE UM FÁRMACO E MÉTODO PARA O TRATAMENTO E/OU PREVENÇÃO DO CÂNCER. Um objetivo da presente invenção é fornecer um medicamento para o tratamento e/ou prevenção do câncer. Para atingir o objetivo, a presente invenção provê um medicamento para o tratamento e/ou prevenção do câncer compreendendo um anticorpo ou um fragmento do mesmo possuindo reatividade imunológica com a proteína CAPRIN-1, e um inibidor de checkpoint imunológico em conjunto ou separadamente em combinação. MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER, AGENTS THAT INCREASE THE EFFICACY OF A DRUG AND METHOD FOR THE TREATMENT AND/OR PREVENTION OF CANCER. An object of the present invention is to provide a medicament for the treatment and/or prevention of cancer. To achieve the objective, the present invention provides a medicament for the treatment and/or prevention of cancer comprising an antibody or a fragment thereof having immune reactivity with the CAPRIN-1 protein, and an immune checkpoint inhibitor together or separately in combination. .

Medicament for treatment and/or prevention of cancer

The present invention addresses the problem of providing a medicament for the treatment and/or prevention of cancer. The present invention relates to a medicament for the treatment and/or prevention of cancer in cancer patients who have a past history of another cancer treatment, said medicament being characterized by containing a combination of an angiogenesis inhibitor or an angiogenesis inhibitor and a taxane drug with an antibody or a fragment thereof having an immunological reactivity with a CAPRIN-1 protein, either separately or in a combined form.

Medicament for treatment and/or prevention of cancer

The present invention addresses the problem of providing a medicinal composition for the treatment and/or prevention of cancer. The present invention provides a medicament for the treatment and/or prevention of cancer in cancer patients who have a past history of another cancer treatment, said medicament being characterized by containing a combination of a pyrimidine drug and carboplatin with an antibody or a fragment thereof having an immunological reactivity with a CAPRIN-1 protein, either separately or in a combined form.

Method to detect cancer

Un método para detectar un cáncer, que comprende medir la expresión de un polipéptido que tiene una reactividad de unión mediante un reacción antígeno-anticuerpo a un anticuerpo contra una proteína CAPRIN-1 que tiene una cualquiera de las secuencias de aminoácidos mostradas en las SEC ID Nº 2 - 30 con numeración par en la lista de secuencias, en una muestra de suero, plasma sanguíneo, fluido ascítico o efusión pleural separada de un organismo vivo, en el que la expresión del polipéptido se mide por inmunoensayo de un anticuerpo que puede estar contenido en la muestra de suero, plasma sanguíneo, fluido ascítico o efusión pleural y se induce in vivo contra el polipéptido a medir A method of detecting a cancer, comprising measuring the expression of a polypeptide that has a binding reactivity by an antigen-antibody reaction to an antibody against a CAPRIN-1 protein that has any one of the amino acid sequences shown in SEQ ID. No. 2-30 with even numbering in the sequence list, in a sample of serum, blood plasma, ascites fluid or pleural effusion separated from a living organism, in which the expression of the polypeptide is measured by immunoassay of an antibody that may be Serum content, blood plasma, ascites fluid or pleural effusion and is induced in vivo against the polypeptide to be measured

Pharmaceutical composition for treating and/or preventing cancer

According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen protein as an agent for treating and/or preventing a cancer is provided. Specifically, the present invention provides a pharmaceutical composition for treating and/or preventing a cancer, which comprises an antibody or a fragment thereof as an active ingredient having immunological reactivity with a partial polypeptide of CAPRIN-1, wherein CAPRIN-1 is represented by any of the even-numbered sequences of SEQ ID NOS: 2 to 30, and wherein the partial polypeptide comprises the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence.

Novel cancer antigen peptide and the use thereof

A novel peptide which is useful as a remedy and/or preventive for cancer and its medicinal use are disclosed. Such a peptide has a contiguous amino acid sequence from a specific region, i.e., the region of aa 10-19, aa 49-61, aa 74-83, aa 96-117, aa 152-161, aa 177-185, aa 202-211, aa 246-261 or aa 326-354 of YKL-40 antigen expressed on the surface of a brain tumor cell, and has an immunity induction activity. Such a peptide is useful for treating and/or preventing cancer by being administered to a living organism, and is also useful for inducing a T cell exhibiting a cytotoxic activity against a cancer cell by in vitro stimulation of the T cell.

Immune response inducer

Disclosed is an immune response inducer comprising a specific polypeptide as an active ingredient. The polypeptide is isolated as a polypeptide capable of binding to an antibody that occurs specifically in a serum collected from a cancer-carrying living body, by the SEREX method using a cDNA library derived from a canine testis and a serum collected from a cancer-carrying dog. The polypeptide can induce an immune response in a living body, and can also regress a tumor in a cancer-carrying living body. Therefore, the polypeptide is particularly useful as a therapeutic and/or prophylactic agent for cancer.

Immune response inducer

An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or prophylactic agent for a cancer(s).

Immune response inducer

An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or prophylactic agent for a cancer(s).

Immune response inducer

An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or prophylactic agent for a cancer(s).

Immunity-inducing agent

The invention relates to an immunity-inducing agent comprising, as an active ingredient, at least one polypeptide having immunity-inducing activity that is selected from among polypeptides (a), (b), and (c): (a) a polypeptide of at least seven contiguous amino acids of the amino acid sequence shown by any even SEQ ID number selected from SEQ ID NOs: 2 to 30 listed in the Sequence Listing; (b) a polypeptide of at least seven amino acids having 90% or more sequence identity with the polypeptide (a); and (c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof, or a recombinant vector comprising a polynucleotide encoding said polypeptide and capable of expressing said polypeptide in vivo .

Painting device for tunnel inner wall

(57)【要約】 【課題】 遺伝子組換えインターフェロンーγの製造方 法を提供する。 【解決手段】 インターフェロンーγ遺伝子組換えバキ ュロウイルスを酸またはアルカリ処理により不活化し、 それにより失活したインターフェロンーγを中性、低温 下で保存することにより活性型インターフェロンーγを 製造する。

Immune response inducer

An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method 5 using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or 10 prophylactic agent for a cancer(s).

Method for detection of cancer

A method for detecting a cancer(s) based on an expression of prescribed polypeptides is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing 5 dog, as a polypeptide which binds to an antibody existing in serum derived from cancer-bearing living body. Because these polypeptides react with antibodies specifically existing in serum of a cancer patient, cancers in a living body can be detected by measuring the antibody in a sample. Cancers in a living body can also be detected by measuring the antigen protein of the antibody per se or mRNA 10 encoding it.

Immune response inducer

Immune Response Inducer

An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method 5 using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or 10 prophylactic agent for a cancer(s).

Immunity-inducing agent

The invention relates to an immunity-inducing agent comprising, as an active ingredient, at least one polypeptide having immunity-inducing activity that is selected 5 from among polypeptides (a), (b), and (c): (a) a polypeptide of at least seven contiguous amino acids of the amino acid sequence shown by any even SEQ ID number selected from SEQ ID NOs: 2 to 30 listed in the Sequence Listing; (b) a polypeptide of at least seven amino acids having 90% or more sequence identity with the polypeptide (a); and (c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof, or 10 a recombinant vector comprising a polynucleotide encoding said polypeptide and capable of expressing said polypeptide in vivo.

Pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment of gallbladder cancer

Provided is antibody effective for the treatment and/or prevention of gall bladder cancer. A pharmaceutical composition for the treatment and/or prevention of gall bladder cancer, including as an effective component thereof: an antibody having immunological reactivity to a CAPRIN-1 protein or a fragment thereof including at least seven continuous amino acid resides in an amino acid array of said protein; or a fragment thereof.

Pharmaceutical composition for treatment and/or prophylaxis of cancer

An object of the present invention is to prepare an antibody that targets specifically expressed on the surface of cancer cells and is superior in antitumor activity to conventional antibodies and to provide use of the antibody as a therapeutic and/or preventive agent for cancer. The present invention provides use of an antibody targeting an identified cancer antigenic protein specifically expressed on the surface of cancer cells as a therapeutic and/or preventive agent for cancer, specifically, a pharmaceutical composition for treatment and/or prevention of cancer, comprising as an active ingredient an antibody or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein, the antibody or the fragment thereof comprising a heavy chain variable region comprising amino acid sequences represented by SEQ ID NOs: 5, 6, and 7 and a light chain variable region comprising amino acid sequences represented by SEQ ID NOs: 9, 10, and 11.

Immune response inducer

An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides of SEQ ID NOs:26, 28 and 30 were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer- bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or prophylactic agent for a cancer(s).

Pharmaceutical composition for treatment and/or prophylaxis of cancer.

La presente invención proporciona un anticuerpo que se dirige a una proteína antigénica cancerosa, específicamente expresada sobre la superficie de las células cancerosas, y el uso del mismo como un agente terapéutico y/o preventivo para el cáncer. Más específicamente, la presente invención proporciona un anticuerpo, o un fragmento del mismo que tiene reactividad inmunológica con un polipéptido CAPRIN-1 parcial que consiste de la secuencia de aminoácidos mostrada por la SEQ ID No.: 5 o una secuencia de aminoácidos que tiene 80 % o más de identidad secuencial a la secuencia de aminoácidos, y una composición farmacéutica para el tratamiento y/o prevención del cáncer, que comprende la misma, como un ingrediente activo.

Immunity induction agent

Provided is a novel immunity inducing agent that is useful as a cancer treatment and/or prevention agent or the like. The immunity inducing agent contains, as an active ingredient: at least one polypeptide having immunity inducing activity and selected from polypeptides (a), (b), and (c), namely, (a) a polypeptide comprising at least seven successive amino acids in the amino acid sequence indicated by sequence number 4, 2, 8, 10, or 12 in the sequence table, (b) a polypeptide comprising at least seven amino acids and having a sequence identity of at least 85% with respect to polypeptide (a), and (c) a polypeptide containing polypeptide (a) or (b) as a partial sequence; or a recombinant vector that can express the polypeptide in vivo and contains a polynucleotide that codes for the polypeptide.

Cancer detection method

Medicament for treatment and/or prevention of cancer

An object of the preset invention is to provide a medicament for treatment and/or prevention of cancer. The present invention relates to a medicament for treatment and/or prevention of cancer in a cancer patient with a previous history of another cancer treatment, comprising an antibody or a fragment thereof haying an immunological reactivity with CAPRIN-1 protein, and an angiogenesis inhibitor or an angiogenesis inhibitor and a taxane-based drug together or separately in combination.

Medicament for treating and/or preventing cancer

This invention relates to a medicament for treating and/or preventing a cancer, comprising a combination of an antibody against a cancer antigen CAPRIN-1 protein that is specifically expressed on the surface of the cancer cell, and an antitumor agent, wherein the antibody and the antitumor agent are combined together or separately, and to a use of the medicament.

Pharmaceutical composition for treatment and prevention of cancer

Pharmaceutical composition comprising anti-caprin-1 antibody for treatment and prevention of cancers

The present invention relates to a pharmaceutical composition for treatment and/or prevention of cancer, which comprises, as an active ingredient, an antibody or fragment thereof having an immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising 7 or more consecutive amino acids.

Pharmaceutical composition for treating and/or preventing cancer

According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen protein as an agent for treating and/or preventing a cancer is provided. Specifically, the present invention provides a pharmaceutical composition for treating and/or preventing a cancer, which comprises an antibody or a fragment thereof as an active ingredient having immunological reactivity with a partial polypeptide of CAPRIN-1, wherein CAPRIN-1 is represented by any of the even-numbered sequences of SEQ ID NOS: 2 to 30, and wherein the partial polypeptide comprises the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence.

Cancer detection method.

La presente invención se refiere a un método para detectar un cáncer, caracterizado porque comprende medir el nivel de expresión de CAPRIN-1 en una muestra biológica a través de reacción antígeno-anticuerpo utilizando un anticuerpo, o un fragmento de unión a antígeno del mismo, que tiene reactividad inmunológica con un polipéptido que tiene la secuencia de aminoácidos mostrada en la SEQ ID NO. 6; y determinar la presencia del cáncer activado por el anticuerpo cuando un nivel de expresión de CAPRIN-1 medido es significativamente más alto que el de un individuo sano, en donde el cáncer es al menos un cáncer seleccionado del grupo que consiste de cáncer de hígado, cáncer de páncreas y cáncer de próstata.

Pharmaceutical composition for the treatment and / or prevention of cancer

Medicinal composition for treating and/or preventing cancer

Method for detection of cancer

A method for detecting a cancer(s) based on an expression of prescribed polypeptides is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer- bearing dog, as a polypeptide which binds to an antibody existing in serum derived from cancer-bearing living body. Because these polypeptides react with antibodies specifically existing in serum of a cancer patient, cancers in a living body can be detected by measuring the antibody in a sample. Cancers in a living body can also be detected by measuring the antigen protein of the antibody per se or mRNA encoding it.

Pharmaceutical composition for treating and/or preventing cancer

According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen protein as an agent for treating and/or preventing cancer is provided. Specifically, the present invention provides a pharmaceutical composition for treating and/or preventing a cancer, which comprises an antibody or a fragment thereof as an active ingredient having immunological reactivity with a partial polypeptide of CAPRIN-1, which is represented by any of even-numbered sequences of SEQ ID NOS: 2 to 30, wherein the polypeptide has the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 37.

Pharmaceutical composition for treating and/or preventing cancer

Immunity-inducing agent and method for detection of cancer

Disclosed is an immunity-inducing agent comprising a recombinant vector as an active ingredient, wherein the recombinant vector comprises at least one polypeptide having an immunity-inducing activity or a polynucleotide encoding the polypeptide and enables the expression of the polypeptide in vivo, and wherein the polypeptide is selected from the following polypeptides (a) to (c): (a) a polypeptide which comprises at least seven contiguous amino acid residues contained in an amino acid sequence depicted in any odd SEQ ID number selected from SEQ ID NO:3 to SEQ ID NO:95 listed in the Sequence Listing; (b) a polypeptide which has a 90% or more sequence identity with the polypeptide (a) and comprises at least seven amino acid residues; and (c) a polypeptide which contains the polypeptide (a) or (b) as a partial sequence thereof.  The immunity-inducing agent can be used for the treatment and/or prevention of cancer.  Each of the above-mentioned polypeptides can react with an antibody occurring specifically in the serum collected from a cancer patient.  Therefore, cancer in a living body can be detected by measuring the antibody in a sample.

Pharmaceutical composition for treatment and/or prevention of cancer

Method for detecting cancer

Pharmaceutical composition for treatment and/or prophylaxis of cancer

This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof as a therapeutic and/or preventive agent for cancer. More specifically, the present invention provides an antibody, or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence shown by SEQ ID NO: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence, and a pharmaceutical composition for treatment and/or prevention of cancer comprising the same as an active ingredient.

pharmaceutical compositions, antibodies, pharmaceutical combination, methods for treating and / or preventing cancer, uses of a pharmaceutical composition, use of an antibody and use of a pharmaceutical combination

COMPOSIÇÕES FARMACÊUTICAS, ANTICORPOS, COMBINAÇÃO FARMACÊUTICA, MÉTODOS PARA TRATAR E/OU PREVENIR UM CÂNCER, USOS DE UMA COMPOSIÇÃO FARMACÊUTICA, USO DE UM ANTICORPO E USO DE UMA COMBINAÇÃO FARMACÊUTICA A presente invenção identifica uma proteína antígeno do câncer que é especificamente expressa sobre as superfícies de células cancerosas e, fornece um uso de um anticorpo que tem como alvo a proteína antígeno do câncer. Especificamente, é revelada uma composição farmacêutica para tratar e/ou prevenir um câncer, que é caracterizada por conter, como um ingrediente ativo, um anticorpo que é imunologicamente reativo com um polipeptídeo parcial da CAPRIN-1, representada pelas sequências pares numeradas como SEQ ID NOs: 2 a 30, dito polipeptídeo parcial compreende a sequência de aminoácido representada pela SEQ ID NO: 37 ou uma sequência de aminoácido possuindo 80% ou mais de identidade de sequência com a sequência de aminoácido ou um fragmento do anticorpo.

Immunity-inducing agent and method for detection of cancer

Method for detecting pancreatic cancer

The present invention relates to a method for detecting pancreatic cancer that utilizes a novel tumor marker. More specifically, the present invention provides the following: a method for detecting pancreatic cancer that includes assaying for the existence or the quantity of a reactive polypeptide that binds with an antibody against the CAPRIN-1 protein through an antigen-antibody reaction in a sample isolated from a test subject; a reagent for detecting pancreatic cancer including an antibody against the CAPRIN-1 protein or a fragment thereof, and a polynucleotide that codes for such an antibody; and a kit.

Cancer detection method

Disclosed is a cancer detection method comprising measuring the expression of a polypeptide in a sample separated from a living body, wherein the polypeptide has a reactivity to bind, through an antigen-antibody reaction, to an antibody directed against CAPRIN- 1 protein comprising an amino acid sequence depicted in any even-numbered sequence selected from SEQ ID NO:2 to SEQ ID NO:30 shown in the Sequence Listing. Also disclosed is a cancer detection reagent comprising CAPRIN-1 protein or a fragment thereof, an antibody directed against CAPRIN-1 protein or the fragment thereof, or a polynucleotide encoding CAPRIN- 1 protein or the fragment thereof.

Pharmaceutical composition for treatment and prevention of cancer

An antibody or a fragment thereof having immunoreactivity to a polypeptide comprising not less than 7 continuous amino acids in the CD179b protein, which was identified as a cancer antigen protein specifically expressed on the surfaces of cancer cells, can be used as a pharmaceutical composition for therapy and/or prophylaxis of cancer.